Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis to market JE vaccine

Novartis to market JE vaccine

31st March 2009

Novartis will market a vaccination which could protect thousands of travellers’ lives who go to Asia.

As part of a strategic alliance between the company and Intercell, Ixiaro is designed to protect against Japanese Encephalitis (JE) and has now been approved by the Food and Drug Administration (FDA).

In clinical trials, the vaccination was shown to provide a protective immune response to the mosquito-borne flaviviral infection in up to 99 per cent of subjects after two doses.

“Asia is now the second most popular travel destination globally – and travel to the region is expected to increase,” remarked chief executive officer of Novartis’ vaccines and diagnostics division.

“JE is spread by mosquitoes, which makes it unpredictable. Vaccination is the most effective preventive measure against the disease.”

This week, the FDA approved Afinitor for patients with advanced renal cell carcinoma who have not been responsive to Sutent or Nexavar.

Robert J Motzer, principal investigator of the drugs’ trial, asserted the ruling would provide a “new and useful tool” for managing the disease.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.